Abstract
To the Editor: Older adults can comprise up to 13% of patients with atopic dermatitis (AD).1 Therefore, clinical trials of AD therapeutics need to adequately include adults over the age of 65 years to ensure that they are treated with medications, the safety and efficacy of which have been explicitly evaluated in their age group. Unfortunately, older adults are often underrepresented in clinical trials across numerous diseases,2,3 including those of systemic AD therapies (azathioprine, methotrexate, and mycophenolate mofetil).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
